BioVisioN and AstraZeneca establish biomarker collaboration
Independent biotechnology company BioVisioN, of Hannover in Germany, and AstraZeneca have signed a collaboration agreement focusing on the discovery of new biomarkers of inflammatory disease.
Independent biotechnology company BioVisioN, of Hannover in Germany, and AstraZeneca have signed a collaboration agreement focusing on the discovery of new biomarkers of inflammatory disease.
BioVisioN will apply its unique phenotyping approach, which is based on the high resolution profiling of peptides and small proteins. It combines BioVisioN's proprietary Peptidomics technology with other quality-controlled processes and bioinformatics into a powerful analysis tool for the correlation with clinical condition and/or therapeutic outcomes.
'This collaboration combines AstraZeneca's expertise on the pathophysiology of inflammatory diseases and access to clinically well defined diagnostic samples with the expertise of BioVisioN on the discovery and the validation of peptidic biomarkers,' said Dr Sven Rohmann, ceo of BioVisioN. 'We look forward to applying our experience and the tools we have developed to search for novel biomarkers of inflammatory disease.'